CervoMed Inc.

CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that selectively inhibits the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction. The company is currently focused on dementia with Lewy bodies (DLB), its lead indication, as well as non-fluent variant primary progressive aphasia (nfvPPA), recovery after stroke (RAS), and amyotrophic lateral sclerosis (ALS). DLB is the second most common progressive dementia after Alzheimer's disease, representing approximately 10-20% of all dementia cases and affecting millions worldwide, with no approved therapies in the US or European Union.

CervoMed believes it is a leader in developing a treatment for DLB, a disease with no approved therapies in the US or European Union. Neflamapimod is the only clinical drug candidate that, to the company's knowledge, has shown statistically significant improvements on clinical endpoints and a biomarker of neurodegeneration in both a Phase 2a and Phase 2b clinical trial. The company believes it is the only company specifically targeting the treatment of DLB patients without Alzheimer's disease co-pathology. With regard to public biopharmaceutical companies considered competitive, the company is aware of Cognition Therapeutics, Inc., although their lead indication remains Alzheimer's disease, and a recent NIA-supported Phase 2 clinical trial of nilotinib. The company is not aware of any other companies developing a treatment specifically targeting DLB patients without AD co-pathology or utilizing its mechanism of action.

CervoMed generates revenue from government contracts, specifically a grant from the National Institute on Aging (NIA) that reimburses the company for certain allowable costs for funded projects. The company recognizes funding received from the NIA Grant as grant revenue, rather than as a reduction of research and development expenses. To date, the company has not generated any revenue from product sales and does not expect to do so in the near future. The company's primary customer segment is the NIA, and its operations are centered on the research and development of its lead drug candidate, neflamapimod.

CervoMed's lead drug candidate is neflamapimod, an investigational, orally administered small-molecule drug that selectively inhibits the enzyme p38α. Neflamapimod is currently in clinical development for the treatment of DLB, its lead indication, as well as nfvPPA, RAS, and ALS. The company's pipeline includes a planned Phase 3 trial in DLB, a Phase 2a trial in nfvPPA, a Phase 2a RESTORE Trial in RAS, and the inclusion of neflamapimod in the EXPERTS-ALS platform. The company also has an issued patent in the US for novel co-crystals of neflamapimod, expiring in 2038 ¹, which could provide additional patent protection if developed.

In November 2025, CervoMed announced alignment with the FDA on key aspects of its planned Phase 3 clinical trial of neflamapimod for the treatment of DLB. The company plans to initiate a single, global, randomized, double-blind, placebo-controlled Phase 3 clinical trial in approximately 300 ² participants in the second half of 2026, subject to available funding. In February 2026, the company announced that neflamapimod has been selected for inclusion in EXPERTS-ALS, a platform funded by the UK government and leading charities. On May 12, 2025, the company entered into a Sales Agreement with Leerink Partners, LLC, to offer and sell shares of common stock with an aggregate offering price of up to $50.0 million ³ under an at-the-market offering program. During the year ended December 31, 2025, the company sold 550,000 ⁴ shares of common stock for proceeds of $4.7 million ⁵, net of $0.1 million ⁶ of issuance costs.

For the year ended December 31, 2025, CervoMed reported a net loss of $27.0 million ⁷, compared to a net loss of $16.3 million ⁸ for the year ended December 31, 2024. Grant revenue was $4.0 million ⁹ in 2025, down from $9.7 million ¹⁰ in 2024. Total operating expenses increased to $32.3 million ¹¹ in 2025 from $28.0 million ¹² in 2024. The company had an accumulated deficit of $97.7 million ¹³ as of December 31, 2025, and cash, cash equivalents, and marketable securities of approximately $20.9 million ¹⁴.

CervoMed's primary growth vector is the advancement of neflamapimod through clinical development for multiple indications. The company plans to initiate a single Phase 3 clinical trial of 32 weeks duration in approximately 300 ¹⁵ patients with DLB without AD co-pathology in the second half of 2026, subject to available funding. The company also plans to advance clinical development for other disease indications, including nfvPPA, RAS, and ALS. For nfvPPA, the company expects to report initial plasma biomarker data in mid-2026 ¹⁶ and topline clinical and biomarker data in the first half of 2027 ¹⁷. For RAS, the company anticipates completing enrollment at the end of the second quarter of 2026 ¹⁸ and expects to report topline data in the second half of 2026 ¹⁹. For ALS, the company anticipates the first patient will be dosed with neflamapimod in the EXPERTS-ALS trial in the fourth quarter of 2026 ²⁰, subject to available funding.

CervoMed's second major growth vector is exploring strategic collaborations to maximize neflamapimod's potential value, support its development, and expedite commercialization, if approved. The company intends to explore potential strategic collaborations in parallel with its planned clinical development program, which may include region- or indication-specific partnerships. The company also believes that novel co-crystals of neflamapimod may provide additional optionality to multiple aspects of its development strategy, including partnering and/or commercialization.

CervoMed does not provide specific margin or cost outlook figures in the filing. The company expects its research and development expenses to increase substantially for the foreseeable future as it continues to invest in research and development activities related to developing neflamapimod, such as conducting larger clinical trials and seeking regulatory approval. The company also anticipates that its general and administrative expenses will increase in the future as it increases headcount to support continued research and development activities.

CervoMed does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations (CMOs) for the manufacture of neflamapimod drug substance and drug product. The company has recently begun working with a second drug substance CMO and a second drug product CMO to diversify its prior sole supplier risk. The company has implemented a controlled manufacturing process to reliably manufacture drug substance that contains only (or predominantly) the most stable polymorphic form of neflamapimod. As of December 31, 2025, the company had 15 ²¹ employees, all full-time.

CervoMed's capital allocation strategy is focused on funding its research and development activities. The company expects to spend substantial amounts to complete the development of, seek regulatory approvals for, and commercialize neflamapimod. The company's primary uses of cash are to fund operations, which consist primarily of research and development expenditures. The company does not have a dividend policy and does not anticipate paying any cash dividends in the foreseeable future. The company has a Sales Agreement with Leerink Partners, LLC, to offer and sell shares of common stock with an aggregate offering price of up to $50.0 million ²² under an at-the-market offering program.

CervoMed faces significant headwinds related to its need for additional capital. The company believes its existing cash, cash equivalents, and marketable securities on hand as of December 31, 2025, will not be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance of the financial statements. This raises substantial doubt about the company's ability to continue as a going concern. The company will require additional financing to advance its current product candidates through clinical development and to fund operations for the foreseeable future.

CervoMed faces execution risks related to the development and commercialization of drug products, which is subject to extensive regulation. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. The company's ability to successfully develop drugs for DLB and other age-related brain disorders is subject to a number of unique challenges, including the limited success in drug development in this field. The company also faces risks related to its reliance on third parties for the production of neflamapimod, which may result in delays in clinical trials or regulatory approvals.

CervoMed faces material risks related to its need for additional capital, as its existing cash, cash equivalents, and marketable securities of $20.9 million ²³ as of December 31, 2025, are not expected to fund operations for at least twelve months from the issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern. The company is heavily dependent on the success of neflamapimod, which is still under clinical development, and if it does not receive regulatory approval or is not successfully commercialized, the business will be materially harmed. The company has concentrated its research and development efforts on DLB, a disease that has seen limited success in drug development, and its rationale for neflamapimod in DLB is based on a scientific understanding that may be wrong. The company faces significant competition from other biotechnology and pharmaceutical companies, and its operating results will suffer if it fails to compete effectively. The company also faces risks related to its reliance on third parties for the production of neflamapimod, which may result in delays in clinical trials or regulatory approvals.

Management's message emphasizes the company's differentiated approach to treating neurodegenerative disorders by focusing on reducing the impact of neuroinflammation in patients with synaptic dysfunction who do not have significant, irreversible neuronal loss. Key strategic priorities include capitalizing on neflamapimod's unique properties to progress its development for age-related brain disorders with high unmet medical need, advancing clinical development of neflamapimod as a potential first-in-class treatment for DLB without AD co-pathology, advancing clinical development for other disease indications such as nfvPPA, RAS, and ALS, and exploring strategic collaborations to maximize neflamapimod's potential value. Management highlights the alignment with the FDA on key aspects of the planned Phase 3 clinical trial and the selection of neflamapimod for inclusion in the EXPERTS-ALS platform as key validation points.